Abstract Introduction Clinical trials that led to the Food and Drug Administration (FDA) approval of systemic cancer therapies have generally excluded patients with autoimmune disease (AID) due to concerns about increased immune-related adverse events (irAEs), disease flares, and potential reductions in the efficacy of immunotherapies. Objective To evaluate the optimal...